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Abstract: Pain in trigeminal areas is driven by nociceptive trigeminal afferents. Transduction
molecules, among them the nonspecific cation channels transient receptor potential vanilloid 1
(TRPV1) and ankyrin 1 (TRPA1), which are activated by endogenous and exogenous ligands, are
expressed by a significant population of trigeminal nociceptors innervating meningeal tissues.
Many of these nociceptors also contain vasoactive neuropeptides such as calcitonin gene-related
peptide (CGRP) and substance P. Release of neuropeptides and other functional properties are
frequently examined using the cell bodies of trigeminal neurons as models of their sensory endings.
Pathophysiological conditions cause phosphorylation, increased expression and trafficking of transient
receptor potential (TRP) channels, neuropeptides and other mediators, which accelerate activation of
nociceptive pathways. Since nociceptor activation may be a significant pathophysiological mechanism
involved in both peripheral and central sensitization of the trigeminal nociceptive pathway, its
contribution to the pathophysiology of primary headaches is more than likely. Metabolic disorders
and medication-induced painful states are frequently associated with TRP receptor activation and
may increase the risk for primary headaches.
Keywords: transient receptor potential vanilloid 1; transient receptor potential ankyrin 1; calcitonin
gene-related peptide; primary headaches; trigeminal system; nociception
1. Anatomical Basis of Headache Generation
Primary headaches such as tension-type headache, migraine or trigemino-autonomic headaches
are clinically well characterized, however, despite intense basic and clinical research, their origin
remains still largely in the dark. In this contribution we ask whether sensitization of nociceptors
may contribute to the generation of primary headaches [1] and how transduction channels of the
transient receptor potential (TRP) type, which are typically expressed in nociceptors [2], are involved
in the expected sensitizing mechanisms. Trigeminal nociceptors are primary afferents originating in
the trigeminal ganglion, which is located in the Meckel’s cave, a cavern on the floor of the middle
cranial fossa. The trigeminal ganglion houses the somata of the primary afferent neurons and gives
rise to three large cranial nerves containing mainly the peripheral axons of pseudo-unipolar primary
afferent neurons, the ophthalmic (V1), the maxillary (V2), and the mandibular (V3) nerve. Like all other
nociceptors, the trigeminal nociceptors consist of small primary sensory neurons with unmyelinated C-
and thinly myelinated Aδ-fibers, the central terminals of which run through the trigeminal nerve, enter
the pontine brainstem and synapse on neurons in the spinal trigeminal nucleus (STN). The STN is
also called trigemino-cervical brainstem complex, because it passes into the upper cervical segments
without clear structural and functional boundary [3,4].
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It is generally held that physiological pain results from activation of nociceptors innervating
peripheral tissues, whereas pathophysiological pain may originate from more central sites of the
nociceptive pathways. The question whether primary headaches belong to one of these categories is
unsolved but most researchers may agree that trigeminal nociceptors are involved in the generation of
headaches [1,5]. It is also widely accepted that nociceptors involved in headache generation innervate
the meninges, although a contribution of nociceptors innervating tissues outside the head and the neck
seems likely (see below). The cranial meninges consist of a delicate inner layer, the pia mater covering
the entire cortical surface, and a tough outer layer bordering the skull, and the dura mater, which forms
also the wall of the cranial sinuses. Between dura and pia mater, the cobweb-like arachnoidea lines the
subarachnoidal space filled with cerebrospinal fluid. All three trigeminal partitions (V1–V3) participate
in innervating the meninges, in the occipital region complemented by cervical afferents from segments
C1–C3. In addition, the meninges are densely innervated also by postganglionic sympathetic fibers
and sparsely by parasympathetic fibers originating in the cranial ganglia [4].
2. Morphology and Role of Meningeal Nociceptors in Headache Generation
The well-known classical intraoperative experiments performed by the groups of Harold Wolff and
Wilder Penfield influenced our understanding of headache generation significantly until recently [6,7].
They observed that headache-like sensations could be elicited from arterial vessels of the dura mater,
dural sinuses and large cerebral arteries, whereas the pia mater was entirely painless, regardless
which noxious stimuli (mechanical, thermal or chemical) were used to stimulate these structures.
There was a discrepancy with morphological data for a long time, since not only dural but also pial
arteries were found to be innervated by thin peptidergic nerve fibers [8,9], which are regarded as
nociceptive (see below). This discrepancy has been solved in recent years, since a French group of
neurosurgeons has collected conclusive data showing that stimulation of pial arterial structures can well
cause painful sensations [10]. In addition to intracranial structures, Wolff’s group reported long ago
that also some extracranial arteries like the temporal artery can be sources for headache sensations [11],
which is interesting in the light of new morphological findings of a collateral innervation of intra- and
extracranial afferents [12,13].
How are meningeal C- and Aδ-nociceptors characterized morphologically? Like other nociceptors
they form so-called free nerve endings, which in ultrastructural dimensions are sensory axons,
frequently in form of small Remak bundles, i.e., several axons embedded in a more or less continuous
sheath of Schwann cells [8,14]. In the course of the sensory endings innervating peripheral tissues
the Schwann cells show gaps, free areas, where the axolemma has direct contact to the surrounding
tissue, which justifies the term “free” nerve ending (Figure 1A). It is obvious that these free areas
are the sites for neuropeptide release into the surrounding and the sites where the axon exhibits
transduction molecules and is sensitive to environmental noxious stimuli [8]. The accompanying
Schwann cells seem to have also important functions, which may include signaling between axon
and Schwann cell. Assuming that the size and shape of the free axonal areas is variable and can be
regulated by the Schwann cell, it may be speculated that an increase in these gaps can increase the
sensitivity of the nociceptive fiber. Recently it has been reported that specialized glial cells associated
with unmyelinated nociceptive nerve fibers in the skin act even as primary transducers, since they
show mechanosensitive properties and transmit the nociceptive information to the nerve endings [15].
The above morphological characteristics of free nerve endings have been reported in several tissues
such as articular ligaments [16,17], skin [18], teeth [19] and meninges [14,20]; though it is not yet
clear if they characterize specifically nociceptors, because thermoreceptive nerve fibers form also free
nerve endings. Thus, it is possible that the morphology of free nerve endings does not provide any
modality-specific characteristics, so that it is rather the equipment with membrane-bound receptor
molecules that determines the modality (see below).
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Figure 1. Ultrastructural characteristics of meningeal nociceptors. (A) Electron micrograph of a 
cross-sectioned small peripheral nerve fiber bundle in rat dura mater. Two sensory axons (A) are 
fully or partly wrapped by a Schwann cell (SC). The left axon contains two mitochondria and some 
dense-core vesicles (arrows), which most likely contain neuropeptides. The not covered axon 
membrane exposed to the surrounding (consisting mainly of collagen fibers) is probably an area of 
sensory transduction and neuropeptide release (see Figure 2). (B) Immunohistochemical staining of 
rat trigeminal ganglion for TRPA1. TRPA1-immunoreactive neurons are preferably small or 
middle-sized. (C–D) Double immunohistochemical staining for TRPV1 and calcitonin gene-related 
peptide (CGRP) in rat dura mater. Regarding the network of thin afferent fibers accompanying the 
middle meningeal artery (MMA) and its branches, TRPV1 and CGRP immunofluorescence are 
nearly completely co-localized. 
Figure 1. Ultrastructural characteristics of meningeal nociceptors. (A) Electron micrograph of a
cross-sectioned small peripheral nerve fiber bundle in rat dura mater. Two sensory axons (A) are fully or
partly wrapped by a Schwann cell (SC). The left axon contains two mitochondria and some dense-core
vesicles (arrows), which most likely contain neuropeptides. The not covered axon membrane exposed
to the surrounding (consisting mainly of collagen fibers) is probably an area of sensory transduction
and neuropeptide release (see Figure 2). (B) Immunohistochemical staining of rat trigeminal ganglion
for TRPA1. TRPA1-immunoreactive neurons are preferably small or middle-sized. (C–D) Double
immunohistochemical staining for TRPV1 and calcitonin gene-related peptide (CGRP) in rat dura mater.
Regarding the network of thin afferent fibers accompanying the middle meningeal artery (MMA) and
its branches, TRPV1 and CGRP immunofluorescence are nearly completely co-localized.
The question if, and in which way, the activity of meningeal nociceptors determines the intensity
of headaches is a matter of speculation. Meningeal nociceptors are certainly highly active when the
dura mater is lesioned or inflamed, like in meningitis, since inflammatory mediators are very effective
in driving primary and secondary trigeminal activity [21,22]. On the other hand, primary headaches
like migraine and cluster headache can be extremely intense but we have no information about the
level of primary afferent activity in these states. Following experimental cortical spreading depression
(CSD) in rodents, which is regarded as an animal model of the aura phase followed by migraine
attacks, i.e., a “natural” model of migraine generation, the meningeal C-fiber activity is remarkably
low [23]. Therefore, it seems to be rather a matter of central sensitization that decides upon the intensity
of headaches (see below). It may also be that the convergent afferent input from different tissues
to the second order neurons in the spinal trigeminal nucleus (trigemino-cervical complex) is most
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important for the character and the intensity of headaches [24]. For example, strong afferent input from
pericranial muscles and neck muscles is possibly not generating headaches unless there is additional
meningeal afferent input. In a rat model of meningeal nociception, local anesthesia of neck muscles
dramatically reduced the activity of spinal trigeminal neurons with convergent afferent input from the
meninges [25].Int. J. Mol. Sci. 2020, 21, 342 6 of 22 
 
 
Figure 2. Scheme depicting important transduction processes in the nociceptive terminal. Transient 
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terminals. TRPV1 is opened by noxious heat, whereas activation of TRPA1 and TRPM8 is facilitated 
under cold conditions. All TRP channels are also gated by specific endogenous and environmental 
substances. Opening of these transduction channels is followed by local cation inflow causing 
depolarization of the terminal, which can additionally activate voltage-gated cation channels 
inducing exocytosis of neuropeptides (Cav) and generate action potentials (Nav). The TRP channels 
(here TRPV1 as an example) can be sensitized by phosphorylation (P) through several protein 
kinases (protein kinase A, PKA; protein kinase C, PKC; calcium calmodulin kinase II, CaMK II) 
induced by a variety of G-protein coupled receptors (purinergic receptors, P2Y; bradykinin 
receptors, BK-R; prostaglandin receptors, EP-R) or tyrosine kinase associated receptors (tyrosine 
kinase A, TrkA; cytokine receptors). TRP receptors can probably interact (double arrow between 
TRPV1 and TRPA1), thereby causing possibly both cross-sensitization and -desensitization. 
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the central nervous system. By this way neuropeptides are transported into the peripheral terminals, 
where they can be released upon stimulation by calcium-dependent exocytosis and induce 
symptoms of neurogenic inflammation [59,60]; likewise in the central terminals they act as 
neuromodulators contributing to synaptic transmission [61,62]. Receptors are transported as well 
and integrated into the terminal cell membrane, for example serotonin 1B/D (5-HT1B/D) receptors, 
the activation of which counteracts neuropeptide and glutamate release and hence eripheral 
transduction and central neurotransmission [63,64]. 
However, morphological and functional findings suggest that some of the receptor proteins are 
unidirectionally transported to a large extent. For example, CGRP receptor components have been 
found by confocal immunohistochemistry co-localized with axonal markers only in the central but 
not in the peripheral processes of rat trigeminal neurons, which may indicate that they are 
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3. The Trigeminal Ganglion Neuron as a Model for Its Peripheral and Central Terminals
Due to their small diameters, peripheral and central terminals of C- and Aδ-fibers are not
accessible for several essential methods in neuroscience. For example, immunofluorescent intracellular
or membrane-bound molecules associated with C-fibers can be visualized with confocal imaging in
transparent tissues such as the rodent dura mater (Figure 1C,D) but quantifying immunofluorescence is
not reliable in these tissues. Extracellular single fiber recordings can be performed in meningeal tissues
with some special techniques like the tracking method [26,27] but measuring membrane potentials
or currents with micropipettes is virtually impossible. Therefore molecular and neurophysiological
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properties of meningeal afferents are frequently studied by imaging and recording from trigeminal
ganglion neurons in situ, isolated ganglia or in cell culture [26,28,29]. In these cases the soma of the
neuron is regarded as a model of its endings, which is justified in that intracellular and membrane-bound
molecules produced in the cell body are delivered via axonal transport to the peripheral and central
terminals, where transduction and neurotransmission take place. Nevertheless this concept should
be taken with caution, because molecules can be modified or assembled to functional units only in
the terminals (for example the calcitonin gene-related peptide, CGRP, receptor complex) and some
molecules may be transported unilaterally towards the periphery or the central nervous system (for
example brain-derived neurotrophic factor, BDNF). Based on this concept different experimental
approaches can be applied:
3.1. Immunohistochemistry
The trigeminal ganglion has been examined with this technique to detect neuropeptides such as
substance P and calcitonin gene-related peptide (CGRP), long before TRP channels have been cloned
and characterized. Probably the earliest immunohistochemical stainings, shortly after a similar study
about dorsal root ganglia had been published [30], showed 40% of rat trigeminal ganglion with CGRP-
and 20% with substance P-immunoreactivity with nearly 100% co-localization [31]. In the human
trigeminal ganglion nearly half of the neurons was found to be CGRP immunoreactive [32]. Significant
proportions of trigeminal ganglion neurons show immunoreactivity for the transient receptor potential
channels vanilloid 1 (TRPV1) and ankyrin 1 (TRPA1) (Figure 1B). In a comprehensive study on human
trigeminal ganglia the number of neurons with co-localization of CGRP and TRPV1 was dependent
on the age of the individuals with 61% in newborn and 35% in adults [33]. Expression of TRPV1
and neuropeptides seem to be closely related in pathological states, e.g., in inferior alveolar nerve
lesion [34].
3.2. Neuropeptide Release
Trigeminal ganglia in situ or cultivated trigeminal ganglion cells from rodents are frequently used
to measure the release of substances following stimulation with noxious agents that target TRPV1
and TRPA1 receptors [35,36]. Particularly quantification of CGRP release from trigeminal ganglia or
trigeminal cell cultures induced by capsaicin is regarded as a parameter for trigeminal activation and
sensitization [37,38]. CGRP release from trigeminal ganglia has also been used to quantify the effect
of antinociceptive substances like non-steroidal anti-inflammatory drugs and to analyze the mode
of their actions [39]. The release studies are confounded by the fact that the trigeminal ganglion is
wrapped by a double layer of dura mater, which prevents the direct access of stimulating substances
and may hinder the diffusion of released substances into the bath solution.
3.3. Electrophysiological Recordings
In intact animals the trigeminal ganglia can be accessed by recording electrodes pushed through
the cerebral cortex. Using this method, reliable extracellular recordings can be made, while the location
of receptive fields indicates the innervation territories of trigeminal neurons. Threshold lowering,
increase in activity upon suprathreshold stimulation and expansion of receptive fields are indicating
nociceptor sensitization [28].
3.4. Calcium Imaging
Finally, trigeminal ganglion cell cultures have frequently been used to study the molecular
properties of neurons and responses to endogenous and environmental mediators using calcium
imaging [36,37]. Agonists and antagonists specifically targeting TRP receptor channels are employed
to find out the role of TRPs in the neuronal activation [40]. For example, the irritating effect of carvacrol
and eugenol, ingredients of spices, were shown by calcium imaging to result from activation of
TRPA1 [41]. Using DiI tracing, dental primary afferents have been shown responding to hyperosmotic
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stimuli with calcium transients, which were dependent on transient receptor potential melastatin 8
(TRPM8) activation [42].
4. Expression of TRPV1 and TRPA1 and Co-Expression with Neuropeptides
Receptor channels of the TRP family are expressed by significant proportions of trigeminal
ganglion neurons [43,44]. TRP receptors form unspecific cation transduction channels in peripheral
sensory endings and may also be involved in synaptic transmission at the central terminals [45].
Nociceptive afferents can be grouped into peptidergic neurons, most of which express
vanilloid-sensitive transient receptor potential (TRPV1) channels, and non-peptidergic neurons,
which are characterized by their isolectin B4 (IB4) binding. The first group is sensitive to nerve growth
factor (NGF), while the second group is sensitive to glial cell-line derived neurotrophic factor (GDNF)
during the development [46,47]. Apart from the expression of TRPV1, the two groups may be different
in some minor physiological functions like neurotransmitter release [48]. However, this grouping seems
not very clear-cut, since immunostaining has shown considerable overlap of TRPV1 and IB4 binding in
primary afferent neurons of rat and mouse, particularly in the rat trigeminal ganglion [49]. Interestingly,
the authors found 70% of CGRP-immunoreactive neurons colocalized with TRPV1 immunoreactivity
(see Figure 1C,D), which was significantly more compared to dorsal root ganglia and may be one
explanation for the dominant role of CGRP as a signaling neuropeptide in the trigeminal system.
TRPV1 receptor channels are activated by pungent substances like capsaicin or resiniferatoxin,
noxious heat, acids (pH < 5.3), and different endogenous compounds including membrane-derived lipid
metabolites like anandamide (Figure 2) [50]. TRPA1 receptor channels, which are highly colocalized
with TRPV1 in trigeminal neurons, are activated by irritants like mustard oil and cannabinoids [51–53].
TRPA1 can also be activated by volatile substances such as umbellulone of the "headache tree" [54]. Its
functional role in trigeminal nociception is controversial, because there is experimental evidence for a
cooperative effect with TRPV1 in meningeal afferents [55] but also for a dual nociceptive-antinociceptive
effect when recordings were made from spinal trigeminal neurons [56], as discussed below in more detail
(Figure 2). Another member of the TRP receptor family implicated in the migraine pathophysiology is
the TRPM8 that is a cold-sensitive channel activated also by natural and synthetic “cooling” agents,
such as menthol and icilin (Figure 2). Some of the TRPM8-positive cells may also express TRPV1 or
CGRP, but a substantial fraction is not labeled by nociceptive markers [57,58].
5. Functional Significance of Mediator Trafficking to Afferent Fiber Terminals
As discussed above, trigeminal ganglia or isolated ganglion neurons are frequently used as models
of their peripheral (sometimes also central) terminals assuming that most of the signal molecules
expressed in the cell bodies are delivered by axonal transport to the periphery and/or into the central
nervous system. By this way neuropeptides are transported into the peripheral terminals, where
they can be released upon stimulation by calcium-dependent exocytosis and induce symptoms
of neurogenic inflammation [59,60]; likewise in the central terminals they act as neuromodulators
contributing to synaptic transmission [61,62]. Receptors are transported as well and integrated into
the terminal cell membrane, for example serotonin 1B/D (5-HT1B/D) receptors, the activation of
which counteracts neuropeptide and glutamate release and hence eripheral transduction and central
neurotransmission [63,64].
However, morphological and functional findings suggest that some of the receptor proteins are
unidirectionally transported to a large extent. For example, CGRP receptor components have been
found by confocal immunohistochemistry co-localized with axonal markers only in the central but not
in the peripheral processes of rat trigeminal neurons, which may indicate that they are unilaterally
delivered to the central terminals [65], although other data do not support this assumption [66]. As all
these molecules are produced in the cell body, every mechanism interacting with their gene expression
has consequences for the peripheral and central functions of these neurons. For example, CGRP
receptors integrated into the presynaptic membrane of central trigeminal terminals may be activated
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by CGRP released from adjacent terminals of other trigeminal afferents to facilitate neurotransmitter
release and synaptic transmission [67,68]. Another example is BDNF, the expression of which is
enhanced by CGRP in cultured trigeminal neurons [69]. BDNF and other neurotrophic factors have
been found to stimulate the expression of TRPV1 and to increase the sensitivity of TRPV1 and TRPA1
receptor channels in dorsal root ganglion neurons [70] as well as TRPV1-mediated CGRP release
from trigeminal ganglion neurons [47]. BDNF is not specific for the somatosensory system but is
also important for other, e.g., cardiovascular functions [71]. Interestingly, however, BDNF produced
by trigeminal afferents is delivered by axonal transport into the trigeminal nucleus, where it can be
released from central presynaptic terminals and may act on pre- and postsynaptic tyrosine kinase
(TrkB) receptors to facilitate nociceptive transmission [72]. Thus, substances acting on neurons within
the trigeminal ganglion, which is outside the blood-brain barrier, can have considerable impact on the
peripheral and central functions of nociceptive transduction and transmission. This mode of action is
clearly relevant regarding the recent discussion about big molecules like monoclonal antibodies, which
reach the central nervous system only at very low concentrations [73] and are therefore assumed to act
mainly outside the blood-brain barrier inhibiting CGRP signaling and reducing trigeminal functions
involved in migraine [74], as reviewed elsewhere [75,76].
6. Signals Sensitizing Trigeminal Nociceptors—Involvement and Interaction of TRP Receptors
A lower threshold for neuronal activation, indicated as lowered pain threshold of facial areas
one day prior to a migraine attack, can be observed in migraineurs compared with healthy controls
suggesting an altered condition of neuronal excitability [77]. This may occur as result of peripheral
and/or central sensitization of the trigeminal nociceptive pathway. During the initial phase of a
migraine attack the occurrence of throbbing pain may be considered as the consequence of an increased
sensitivity of peripheral trigeminal neurons that innervate the meninges [21]. Physical activities
increasing intracranial pressure generally worsen these symptoms. Previously innocuous stimuli on
the facial skin may be uncomfortable or even painful during a migraine attack. This cutaneous allodynia
is thought developing through the sensitization of second-order neurons in the spinal trigeminal
nucleus, which receive convergent input from meningeal tissues as well as from the facial skin [78,79].
Sensitization of primary sensory neurons may occur through repeated or sustained activation that may
have also a long-lasting effect on the function of the second-order neurons in the trigeminal nociceptive
pathway leading to an increased susceptibility even in the absence of the peripheral sensitizing agent.
Multiple changes in TRPV1 and TRPA1 receptor function may be involved in sensitization of
trigeminal nociceptors (Figure 2). Phosphorylation of the receptors by protein kinase A (PKA) or
protein kinase C (PKC) decreases their activation threshold, leading to an increased open probability
of the ion channels [80,81]. Besides this short-term regulation, intermediate and long-term regulatory
mechanisms also lead to the sensitization of TRP receptors. Phosphorylation of TRPV1 protein stored
in vesicles may accelerate their exocytosis and the insertion of functional TRPV1 receptors into the
cell membrane (see below) [82]. Increasing the amount of TRPV1 or TRPA1 receptors on the surface
membrane contributes to nociceptor sensitization on an intermediate time scale. Effects increasing
receptor protein expression may have long-lasting effect on nociceptor sensitivity [83,84].
Activation of TRPV1 and TRPA1 receptor channels by pungent plant compounds like capsaicin
or substances from mustard and garlic as well as environmental irritants such as formaldehyde and
acrolein [85] go along with inward sodium currents depolarizing the sensory endings and calcium
currents inducing neuropeptide release (Figure 2) [38], which leads to arterial vasodilatation and
increased blood flow [86–88]. One might assume that the released neuropeptides contribute to
nociceptor sensitization. However, CGRP is not activating nociceptors directly and does therefore not
cause pain but seems to contribute only to pain generation after the nociceptive system has already
been sensitized, for example by glycerol trinitrate (GTN), which mimics the action of nitric oxide (NO),
as it was demonstrated by CGRP injection into facial skin in GTN pretreated rats [89].
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Neurogenic inflammation of the meningeal tissue and CSD are pathophysiological conditions
considered as endogenous mechanisms initiating cascades of events that may activate and/or sensitize
nociceptors in the meningeal tissue leading to hypersensitivity and allodynia. In animal models
chemical irritation of the dura mater was found to activate and sensitize meningeal nociceptors [59,90].
Proinflammatory substances play a significant role in these sensitizing processes (Figure 2). Initial
release of neuropeptides from activated nociceptors may potentiate the secretion of proinflammatory
mediators, e.g., by degranulating dural mast cells [91,92]. Electrophysiological recordings showed
that capsaicin-induced neuronal responses are enhanced by prostaglandine E2 and prostacyclin
through the activation of cAMP-dependent protein kinase A (PKA) and protein kinase C (PKC)
pathways [80,93]. PKC activation and consequent phosphorylation seem to be also mechanisms of
ATP- and bradykinin-induced sensitization of nociceptors [94,95].
Chronic migraine patients show elevated levels of NGF in their cerebrospinal fluid [96]. Under
experimental conditions expression of NGF mRNA and release of NGF can be enhanced by sensory
neuropeptides like CGRP [97]. Elevated NGF levels, similarly to insulin and insulin-like growth factor
1 (IGF-1), activate phosphatidylinositol-3-kinase that may lead to phosphorylation of the TRP receptors
through calcium/calmodulin-dependent protein kinase II (CaMKII) and PKC [98,99].
Activation of the tyrosine kinase receptor A (TrkA) by NGF, insulin or IGF-1 initiates a cascade of
events leading to phosphorylation of TRPV1 that is located in intracellular vesicles. This increases
the amount of functional TRPV1 in the cell membrane by increasing its trafficking [100]. Recent
experiments showed upregulation of TRPA1 mRNA in trigeminal ganglion neurons innervating the
dura mater after chronic exposure of rats to an atmosphere containing the TRPA1 agonist acrolein [101].
Interestingly, an increase in TRPV1 protein content but not TRPV1 mRNA was measured following
treatment of trigeminal ganglion neurons with NGF mediated by the mitogen-activated protein kinase
pathway [102].
Calcium inflow into the nociceptors may also lead to desensitization of TRPV1 via
calcium/calmodulin-dependent protein phosphatase 2B (calcineurin) andβ-arrestin-2 [103,104]. Similar
mechanisms may be assumed for TRPA1. Thus, sensitization and desensitization counteract and
may be more or less balanced depending on the state of TRP activation (Figure 2). The situation is
even more complicated in neurons expressing both TRPV1 and TRPA1 [52]. There is evidence that
these two receptor channels interact in that TRPA1 activation limits TRPV1-mediated current but
also desensitization due to the TRPA1-mediated current [105]. Therefore, it seems possible that the
interactions of both channels can both increase or decrease trigeminal nociceptor activity, depending
on the strength of their activation. Extracellular recordings from meningeal afferents revealed a mainly
cooperative effect between TRPV1 and TRPA1 confirmed in TRPV1-deleted mice [55]. Activation
of TRPA1 receptor channels increased the activation threshold and did not cause propagated action
potentials unless TRPV1 was present. These effects may be further modulated in afferent second order
neurons. In a rat model of meningeal nociception, recordings from neurons in the spinal trigeminal
nucleus with meningeal afferent input indicated that individual neurons may be activated or inhibited
by the TRPA1 agonist nitroxyl (HNO, see below) [56]. Thus, the effects of TRPA1 agonists may depend
on the site of action (peripheral vs. central terminals) and the functional characteristics of higher
order neurons.
Single nucleotide polymorphisms associated with the susceptibility for migraine have been
identified in genes coding for TRPV1 and TRPV3 but the pathophysiological relations with known
migraine mechanisms are yet unclear [106]. Besides TRPV1 and TRPA1, TRPM8 receptors are expressed
in TG neurons (Figure 2). TRPM8 is interesting, because genome-wide association studies showed
that it may be implicated in migraine [107,108], i.e., more specifically, single-nucleotide variants near
or within the TRPM8 gene resulting in reduced TRPM8 expression are associated with reduced risk
for migraine [109]. TRPM8 has been identified as a sensor for environmental cold [57] and low body
temperature [110] but experimental work on trigeminal nociceptive functions is contradictory. The
TRPM8 agonist icilin applied onto the rat cranial dura mater induced cutaneous facial and hind paw
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allodynia that was attenuated by systemic pretreatment with a TRPM8 antagonist [111,112]. On the
contrary, TRPM8 activation reversed an increase in facial sensitivity to heat induced by meningeal
inflammation, and in a trigeminal ganglion cell assay TRPM8 activation inhibited TRPV1 effects [101].
Thus TRPM8 activation by exogenous agonists may both aggravate and alleviate headache-related
behaviors, possibly depending on the activation of other pro-nociceptive receptors of meningeal
afferents [58].
In this context it is very interesting that both TRPV1 and TRPM8 receptor channels are differently
involved in the regulation of body temperature [109]. While TRPV1 activation causes a decrease,
TRPM8 activation causes an increase in body temperature; the basal activity of both receptor channels
counteracts excesses of the body temperature, thereby contributing to homeostasis. It is intriguing,
although evolutionary fitting, that single-nucleotide variants causing reduced TRPM8 expression,
which is associated with a higher risk for migraine, are more frequently found in populations that live
in warmer geographic areas [113].
Ten years ago already, several TRPV1 antagonists have entered clinical trials, including ABT-102,
SB-705498, AMG-517, MK2295 and GRC-6211 [114], however, the major setback in the development
of TRPV1 antagonists for the treatment of chronic pain was an elevation of the body temperature.
Attempts to develop TRPV1 antagonists without causing hyperthermia are in the focus of recent
pharmacological research [115].
7. Sensitization of Trigeminal Nociceptors Following Cortical Spreading Depression
Cortical spreading depression (CSD) is characterized by a slowly propagating wave of
depolarization followed by suppression of cortical activity, a complex event, which induces dramatic
changes in neural and vascular functions. CSD has been implicated in the pathophysiology of migraine,
derived from neuroimaging studies which showed changes in cortical blood flow (propagating with
similar velocity as the experimental CSD) during the visual aura phase of migraine [116,117]. Since aura
in most cases precedes the onset of headache, it was hypothesized that CSD may lead to the activation
of meningeal nociceptors [118]. Although animal models provide support for this hypothesis, its
relationship to migraine attacks is still under debate. CSD may stimulate dural nociceptors either by
axon collaterals innervating both the pia mater and the dura mater [119] or by the direct diffusion of
molecules such as potassium ions, hydrogen ions or glutamate released during CSD [120,121]. CSD
may also increase the production of reactive oxygen species in the cortex, in meningeal tissues and also
in the trigeminal ganglion [122]. Low extracellular pH or oxidizing agents may directly activate TRPA1
and TRPV1 channels through modification of cysteine (Figure 2); they excite trigeminal nociceptors
and induce the release of CGRP from trigeminal terminals to promote sensitization of trigeminal
neurons [123]. Recently it was shown that CGRP-binding monoclonal antibodies can prevent the
development of central sensitization and cutaneous allodynia elicited by CSD [124].
In vivo two-photon imaging of anesthetized mice revealed changes in the morphology of
macrophages and motility of dendritic cells in the meninges in relation to CSD [125]. During
CSD, meningeal macrophages changed their shape and migration of dendritic cells stopped, which
was considered as changes in meningeal immune cell function signalizing to the TRPV1 expressing
meningeal nociceptors. These observations are consistent with earlier findings on meningeal immune
cells, where CSD was observed causing degranulation of mast cells and potentiating the activation of
dural nociceptors [126].
8. Role of Metabolic States in Trigeminal Sensitization
Population-based studies indicate that migraine can be associated with metabolic disorders.
Obesity, insulin resistance and diabetes mellitus are conditions that are linked to the primary headache
migraine. These conditions may enhance the frequency and severity of headache attacks and they may
increase the risk for migraine [127,128]. Our knowledge about sensitization of trigeminal nociceptors
in metabolic disorders is based on studies in experimental animals.
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Recent experimental observations indicated that in rats, high-fat high-sucrose (HFHS) diet
increased fasting blood glucose and insulin concentrations as well as levels of the circulating
proinflammatory cytokines interleukin-1β (IL-1β) and interleukin-6 (IL-6). HFHS diet-induced
obesity was associated with enhanced basal and stimulated CGRP release from meningeal nociceptors.
Both TRPV1 and TRPA1 receptor sensitivity to the specific stimulatory agents capsaicin and acrolein,
respectively, was increased. Stimulation of TRPV1 and TRPA1 receptors resulted also in a significantly
augmented vasodilatory response in meningeal blood vessels of obese animals [129,130].
Experimental results indicate that migraine pathophysiology and the conditions leading to the
excess of body fat overlap in several aspects. Adipose tissue produces bioactive molecules, which
serve as regulators of metabolism and also modulate immune functions [131,132]. Since HFHS diet
of experimental animals sensitizes TRP receptor function without obvious changes in density or
distribution of TRPV1-immunoreactive afferents of the dura mater and TRPA1 protein expression in
the trigeminal ganglion, sensitization of the TRP receptors is more likely the consequence of the release
of proinflammatory agents produced by the adipose tissue. IL-1β may directly modify the gating
properties of TRP channels for noxious stimuli in primary sensory neurons but leave the transport of
TRP channels to the plasma membrane unaffected [133].
Streptozotocin injection destroying insulin secreting cells of pancreatic Langerhans islets reduced
the number of TRPV1-immunoreactive nerve fibers of the dura mater in rats [134]. Impairment
of trigeminal nociceptors develops slowly; loss of TRPV1-mediated CGRP release and the lack of
meningeal vasodilatation upon TRPV1 stimulation cannot be observed shortly after the induction of
diabetes, which may be explained by the slow decrease in neuronal peptide levels after treatment
with streptozotocin. In the rat trigeminal ganglion, CGRP markedly declined only five weeks after the
induction of diabetes [135].
Despite the impaired function of chemosensitive trigeminal afferents, clinical observations
indicate that diabetic patients suffer more frequently from headaches than non-diabetics [127]. It was
hypothesized that dysfunction of the afferents may contribute to the enhanced incidence of headaches
in diabetics due to a limited elimination of tissue metabolites and inflammatory mediators from
meningeal tissues.
Another endocrine disorder, hypothyroidism, seems to have a bidirectional association with
migraine. Common genetic and immune mechanisms are considered as underlying pathophysiological
processes [136]. TRP receptor ion channels may function as possible targets for proinflammatory
cytokine effects leading to increased incidence of migraine attacks in hypothyroid patients.
9. Intraganglionic Mechanisms Involved in Nociceptor Sensitization
Migraine attacks can be triggered by the activation of trigeminal afferents innervating extracranial
tissues. Inhaled environmental irritants stimulating TRPA1 receptors of the nasal mucosa, allergic
rhinitis, acute sinusitis and temporomandibular joint disorder are risk factors for migraine [101,137].
Cross-excitation within the trigeminal ganglion may explain why activation of one branch of the
trigeminal nerve can promote cellular changes that result in sensitization within the entire ganglion
and lead to the generation of headaches.
CGRP can be released not only from the peripheral and central terminals of activated trigeminal
neurons but also from the cell body [138]. CGRP released within the ganglion may facilitate spreading
of information throughout the whole ganglion [139]. Within the trigeminal ganglion both neurons
and satellite glial cells can express CGRP receptor components, and accordingly they serve as targets
of CGRP effects. In rats 32% of neurons in the trigeminal ganglion express both calcitonin-like
receptor (CLR) and receptor activity modifying protein 1 (RAMP1) receptor components indicating
the formation of functional CGRP receptors [65]. Neurons expressing CGRP receptor components are
frequently found in close vicinity to CGRP containing neurons, which enable cross-talk between them.
The neurotransmitters glutamate and ATP have also been implicated in the communication within the
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trigeminal ganglion. Experimental studies have demonstrated the expression of excitatory glutamate
receptors and ATP receptors in sensory neurons [140,141].
Besides direct transmission of information from one neuron to the other, activation of satellite
glial cells may provide an additional indirect mechanism for the sensitization of other neurons initially
not involved in the nociceptive process. Glial cells activated by the initial transmitter release from
trigeminal neurons may release inflammatory molecules leading to sensitization of neurons [142].
Glutamate release from satellite glial cells cultured from the trigeminal ganglion was also reported as
intraganglionic signaling mechanism [143].
The TRPV1 receptor agonist endovanilloid/endocannabinoid anadamide and other endogenous
lipid metabolites or inhaled irritants activating trigeminal TRPA1 receptors are well-known mechanisms
leading to activation of some trigeminal neurons [54,144]; their intraganglionic effect may probably
play a significant role in the process of cross-sensitization within the trigeminal ganglion.
10. Sensitization Processes within the Trigeminovascular System
A subpopulation of trigeminal neurons innervating the dura mater express the proteinase-activated
receptor-2 (PAR-2) that may be a target for proteolytic enzymes, e.g., tryptase released from activated
mast cells [145]. Cleavage exposes tethered ligand domains that bind to and activate cleaved receptors.
Since meningeal mast cells are targets for neuropeptide actions, release of CGRP or substance P
from meningeal afferents may degranulate mast cells leading to the release of mast cell tryptase and
consequent PAR-2 activation. Experimental observations indicate that activation of PAR-2 induces
sensitization of the TRPV1 receptor in trigeminal afferents, elicits CGRP release and enhances meningeal
blood flow upon stimulation the TRPV1 receptor with its specific agonist capsaicin [146]. Mast cell
tryptase activating the PAR-2 receptor may sensitize not only TRPV1 but also TRPA1 receptors of
trigeminal afferents. Cleavage of PAR-2 may activate phopholipase C, which unlocks TRP receptors
from phosphatidylinositol-4,5-bisphosphate inhibition [147]. Since also mast cells possess PAR-2
receptors, a mutual activation of mast cells through the released tryptase may initiate a self-triggering
mechanism of mast cells resulting in an amplification of the primary nociceptive response and probably
also the sensitivity of the second-order neurons in the nociceptive pathway [148].
Hydrogen sulfide (H2S) and NO, members of the gasotransmitter family, are involved in the
regulation of a great variety of physiological functions, including cardiovascular functions, nociception
and inflammation [149,150]. A substantial body of evidence indicates that H2S increases the firing rate
of trigeminal ganglion neurons by acting on TRP receptors [56,151]. H2S is synthesized from cysteine
through several enzymatic pathways. The H2S producing enzyme cystathionine β-synthase (CBS) is
abundantly expressed in the trigeminal ganglion of rats [152] and under inflammatory conditions CBS
expression may be upregulated at both protein and mRNA levels [153].
Recent studies reported that H2S produced in peripheral tissue may interact with NO and results
in generation of polysulfides [154,155] or HNO, a protonated, one electron-reduced derivative of
NO [156]. Polysulfides and HNO are activators of TRPA1 receptors. In the dura mater HNO production
and its effect on TRPA1 receptors seems to be the main mechanism of H2S-induced vasodilatation and
CGRP release [157]. In the trigeminal ganglion of rats, CBS immunoreactivity was partly colocalized
with TRPA1 in small trigeminal neurons [152]. Continuous generation of HNO in the meningeal
tissue and its CGRP releasing effect through the activation of TRPA1 seems to be also a significant
vasodilatory component maintaining basal meningeal blood flow [157].
11. Medication-Induced Trigeminal Nociception and Pain
Epidemiological studies indicate that in patients suffering from primary headaches the progressive
increase in the use of acute medication increases the number of headache days per months leading
to medication overuse headache (MOH). All specific migraine and pain medications seem to have
the capacity to cause MOH [158]. Pathophysiological studies in animal models have suggested that
central sensitization of the trigeminal nociceptive pathway may function as a basis for MOH. Central
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sensitization induced by chronic application of drugs like triptans, paracetamol or opiates seems to
underlie the pathogenesis of MOH.
A recent study reports the lack of association between the polymorphisms of TRPV1, TRPA1
and TRPM8 ion channels and MOH in patients [159]. In different animal models of MOH, similar
metabolic changes in the trigeminovascular system were observed; increase in CGRP expression and
decrease in 5-HT1B/D receptor expression [160]. Clinical studies in MOH patients have shown that
5-HT levels decrease, which may subsequently reduce the inhibitory effect mediated by the 5-HT1B/1D
receptors of trigeminal sensory neurons on sensory neuropeptide release [161]. Increased CGRP
release upon TRPV1 or TRPA1 activation induced by their specific agonists may be involved in the
sensitization process.
Drugs used for other purposes than headache therapy may alter the sensitivity of nociceptors
leading to uncomfortable or painful sensations upon administration. The α1-adrenoceptor agonist
phenylephrine used at high concentrations as a mydriatic agent and for the treatment of nasal congestion
may induce local burning sensation or headache as adverse side effect [36]. Recent experiments revealed
that high concentrations of phenylephrine activate trigeminal neurons in rodent models of trigeminal
nociception. This activation induces calcium inflow and consequent CGRP release from trigeminal
neurons innervating the meningeal tissues. As a neurovascular consequence of the peptide release,
increases in meningeal blood flow were recorded. Activation of trigeminal nociceptors was mainly
the result of the activation of TRPV1 receptor channels by phenylephrine. The contribution of TRPA1
receptor activation was excluded, since pretreatment of the dura mater with the TRPV1 receptor
antagonist abolished the phenylephrine-induced CGRP release and meningeal blood flow increase,
while the TRPA1 receptor antagonist had no effect on it. Results obtained in trigeminal neurons of
TRPV1-deficient animals supported this observation. Phenylephrine-induced calcium transients and
CGRP release were abolished in trigeminal ganglion neurons of TRPV1-deficient animals [36].
A potent anthracycline-type antitumor agent, adriamycin, is used in the treatment of various
malignancies [162]. As serious side effects, impairments in sensory nerve functions were reported, which
may also significantly contribute to the cardiomyopathy developing in some patients [163,164]. Recent
findings revealed multiple but selective impairments of receptor functions in the trigeminovascular
system after adriamycin treatment. Adriamycin affected the nociceptor channels TRPV1 and TRPA1 and
also the CGRP receptors of meningeal arteries. While the impairment of chemosensitive nociceptors was
clearly indicated by the reduced TRPV1 content of trigeminal ganglia of adriamycin-treated animals,
in the dura mater whole mount preparations the density and distribution of TRPV1-immunoreactive
afferents were not significantly changed. Measurements of CGRP release in an ex vivo dura mater
preparation revealed an altered dynamic of peptide release upon repeated stimulations of TRPV1
and TRPA1 receptors. The first application of an agonist of TRPV1 or TRPA1 receptor induced a
significantly higher increase in CGRP release in adriamycin-treated animals compared to control
animals, while further applications failed to increase the release [165]. Although headache is not a
major problem among patients treated with adriamycin, and to our knowledge no clinical studies
indicated increased incidence of headache in this population, the impaired trigeminal nociceptor
function coupled with impaired vasodilator capacity of meningeal blood vessels may be an important
mechanism contributing to pain sensation.
12. Synopsis: Relevance of TRPV1 and TRPA1 in Primary Headaches
Clinical observations and animal studies provide evidence for a central role of trigeminal afferents
in the mechanisms of primary headaches [5,166]. A significant population of trigeminal afferents
expressing the nociceptive ion channels TRPV1 and TRPA1 are peptidergic. They contribute not
only to the transmission of the nociceptive information towards the central nervous system but their
neuropeptide content released from their peripheral and central terminals and also from their cell body
upon activation may have a significant modulatory effect on long-term pain perception. Different
peptides (CGRP, substance P or pituitary adenylate cyclase-activating peptide) possessing vasodilatory
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function have been identified in trigeminal neurons [167,168]. Being the most abundant peptide in the
trigeminal system, expressed by approximately 40% of neurons, CGRP has gained major attention
in clinical and experimental studies on the pathomechanisms of primary headaches. Reducing the
release of CGRP, blocking its receptor or binding CGRP with humanized anti-CGRP antibodies seem
to be effective in the treatment or prevention of migraine attacks [76,169]. CGRP released within the
trigeminal ganglion may sensitize other neurons directly or by acting on satellite glial cells. According
to the currently accepted view, meningeal arterial vasodilatation induced by CGRP does not play a
causative role in primary headaches [5]. CGRP-induced meningeal vasodilatation may still have a
beneficial effect, e.g., by removing inflammatory mediators from the meningeal tissue and preventing
or reducing the activation and/or sensitization of the nociceptive pathway. Release of CGRP from
trigeminal nociceptors and initiation of processes leading to peripheral and central sensitization of
the nociceptive pathway can be induced by different endogenous and exogenous agents acting on
TRPV1 or TRPA1 receptors. The important role of TRP receptors in the activation and sensitization of
trigeminal nociceptors make them possible targets for drug developments that counteract the channel
opening or the expression of the channels, thereby reducing CGRP release from trigeminal afferents.
Removing the key mediator CGRP may interrupt the vicious circle leading to increased susceptibility
for headache attacks.
Given that TRPV1 receptor channels play a major role in nociceptive transduction, the question was
if they are also involved in the generation of primary headaches. Therefore, animal models of headache
have been employed, which admittedly provided inconsistent results. Systemic administration of
the TRPV1 antagonist SB-705498 suppressed responses to stimulation of the dura mater and the
facial skin and reversed the sensitization of second order neurons in the spinal trigeminal nucleus
of cats induced by inflammatory compounds [170]. The authors concluded that inhibiting TRPV1
may be useful to treat inflammatory trigeminovascular pain but expressed their skepticism regarding
primary headaches. In two other animal studies in the rat the TRPV1 antagonists JNJ-38893777 and
JNJ-17203212 suppressed the generation of the immediate early gene c-fos, provoked by intracisternal
application of inflammatory mediators, and attenuated the CGRP release into the external jugular
vein following injection of capsaicin into the carotid artery. The authors concluded that TRPV1 may
play a role in the pathophysiological mechanisms relevant to migraine [171]. In contrast, the TRPV1
antagonist A-993610 had no significant effect on the activity of rat spinal trigeminal neurons evoked
by electrical stimulation of the dura mater, did not block neurogenic vasodilatation of dural arteries
and did not cause any change in the CSD response induced by pin prick. Based on these results the
authors concluded that blockade of TRPV1 receptor channels will gain no role in the treatment of acute
migraine [172].
Some volatile agonists of TRPA1 are known to trigger headaches in sensitive persons. The
best known example is the scent of the Californian “headache tree”, Umbellularia california, the
active compound of which, the monoterpene ketone umbellulone, was found to activate TRPA1
receptor channels expressed in HEK293 cells and trigeminal ganglion neurons and to cause nociceptive
behavior in wild-type but not TRPA1-deficient mice [54,173]. Another plant is fewerfew (Tanacetum
parthenium), which has been used for centuries to treat headache and other pains. Its major constituent,
parthenolide, has also been found to stimulate TRPA1 receptor channels but behaves as a partial
agonist, which preferably desensitizes trigeminal neurons [174]. Curcumin, the active principle of
turmeric root (Curcuma longa) also activates and subsequently desensitizes TRPA1 ion channels [175].
Regarding TRPV1, partial agonism was found for two major components of Evodia rutaecarpa,
evodiamine and rutaecarpine, from which the first one reduced capsaicin- and proton-evoked currents
in TRPV1-expressing HEK293 cells [176].
Extracts of the butterbur plant (Petasites hybridus) with the main component isopetasin have long
been used as preventives for migraine [177]. Isopetasin has been shown to induce calcium signals and
inward currents in rodent trigeminal ganglion neurons and CGRP release from mouse dorsal spinal
cord via activation of TRPA1 receptor channels, while pre-exposure to isopetasin attenuated responses
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to the TRPA1 agonist allyl isothiocyanate and the TRPV1 agonist capsaicin in these preparations.
Repeated systemic administration of isopetasin attenuated also mouse facial rubbing evoked by
local allyl isothiocyanate or capsaicin. The authors concluded that activation of TRPA1 channels
by isopetasin and excitation of neuropeptidergic trigeminal neurons causes heterologous neuronal
desensitization, which may account for the anti-migraine effect of petasites extracts [178]. Thus,
regarding the above discussion, the role of TRP receptor channels in headache generation seems to be
ambiguous, and it may be a matter of the balance of sensitizing-desensitizing mechanisms if a TRP
agonist is preferentially triggering or preventing headaches.
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